RE: SP3 Mar 2022 08:35
Our focus will continue to be on serving our contract customers in bringing their products to market, in both Covid and non-Covid indications. We have world-class facilities in both York and Doncaster, with leading-edge high throughput automation and significant in-house expertise in developing, transferring in and scaling-up lateral flow test production.
"We will also continue to market the AbC-19 test for individuals who want to know their antibody status, while remaining ready to scale-up our supply as and when national testing strategies focus on an individual’s antibody levels as a proxy for immunity.
“We strongly believe the lateral flow self-test market will expand significantly, and therefore we are investing in a state-of-the-art e-commerce site to allow B2C distribution of our own and third-party tests, supported by our own in-house validation of these third-party tests.
"In addition, we have made good initial progress in the development of our own self-tests with an initial focus on Influenza, Lyme disease and Hepatitis C."